Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Onconetix (ONCO) Research & Development (2023 - 2025)

Onconetix (ONCO) has disclosed Research & Development for 2 consecutive years, with -$290.0 as the latest value for Q4 2024.

  • On a quarterly basis, Research & Development rose 99.85% to -$290.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $154359.0, a 90.78% decrease, with the full-year FY2024 number at $154359.0, down 92.08% from a year prior.
  • Research & Development was -$290.0 for Q4 2024 at Onconetix, down from $109365.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $1.1 million in Q1 2023 to a low of -$198921.0 in Q4 2023.